

Study refines understanding of T cells' action in HIV immune response



The effect of M-T807R1 administration and RAL monotherapy on blood CD8⁺ T cell dynamics. The effects of M-T807R1 on the dynamics of CD8 cells in individual macaques of a CD8 depletion group (n = 4), b CD8 depletion plus RAL Tx group (n = 8), and c RAL Tx group (n = 8). Vertical dashed lines represent the times of M-T807R1 administration and shaded regions represent the time of RAL monotherapy. d Distributions of the blood CD8⁺ T cell counts



before (after viral load reached steady state) and after the time of first M-T807R1 administration. We used two-sided linear mixed effects to compare the repeated measurements pre- and post-infusion for the n = 4 (CD8 depletion group), n = 8 (each for CD8 depletion plus RAL Tx group, and RAL Tx group). In all the panels, blue for CD8 depletion group; red for CD8 depletion plus RAL Tx group; and gold for RAL Tx group; with different symbols indicating different macaques. In (d) individual data points and box plots are presented. Box plots represent the 25th and 75th percentiles (bottom and top edge of the box), the median (line across the box), whiskers extending from the edge of the interquartile range from the box's edges, and extreme values beyond that shown as crosses. Credit: *Nature Communications* (2023). DOI: 10.1038/s41467-023-42435-8

New research combining computer modeling and experiments with macaques shows the body's immune system helps control human immunodeficiency virus (HIV) infections largely by suppressing viral production in already infected cells while also killing viral infected cells, but only within a narrow time window at the start of a cell's infection.

"To eliminate HIV, we have to understand how the immune system attempts to control the infection," said Ruy M. Ribeiro, a theoretical biologist at Los Alamos National Laboratory who led the development of the model underpinning the research. Ribeiro is the corresponding author of <u>the paper</u> about the findings, published in *Nature Communications*.

The research team included Los Alamos Senior Fellow Alan S. Perelson and a former Los Alamos postdoctoral researcher now at the Fred Hutchinson Cancer Research Center. Their collaborators at the University of Pittsburgh managed the experiments with <u>macaques</u> infected with simian immunodeficiency virus (SIV) to validate the



model. SIV infections in monkeys behaves the same way as HIV in humans.

Helping the immune system attack HIV

"The immune system can't eliminate an HIV infection," Ribeiro notes, "but pinpointing the existing mechanism by which it is to some extent controlling HIV is very important for designing treatments to enhance that mechanism. If we can modulate the <u>immune system</u> to help control HIV better, we may be able to cure the disease at some point."

Under the overall leadership of Perelson, Los Alamos has been a global leader in modeling <u>viral infections</u>, including HIV, since the mid-1990s. For the *Nature Communications* paper, the research team extended a <u>mathematical model</u> published in 2017 by Ribeiro and others at Los Alamos that simulates the interactions and lifecycle of cells that will be infected, already infected cells and the virus.

The new model also simulates the potential effects of the immune response, which include killing the cells, generating proteins that suppress the production of virus or helping mount a defense that prevents the virus entering cells.

Resolving an open question about HIV

Specifically focused on a kind of immune response mediated by CD8⁺ T cells, the research resolved an open question in HIV research: Do these T cells control HIV by killing HIV cells or by triggering human cells to deploy defenses against the infection?

"There's been controversy about whether this type of T cell controls infection by killing infected cells or by somehow controlling the virus



without killing infected cells, so we're trying to distinguish these possibilities and mechanisms," Ribeiro said.

The answer turned out to be "a little of both."

To isolate the role of the T cells, the Los Alamos team ran the model to predict the effects of treating groups of infected macaques variously with antibodies and <u>antiviral drugs</u>.

Some macaques were treated with a drug designed to prevent infection by blocking the virus from integrating into the DNA of the macaques' cells. This drug, called an integrase inhibitor, "revealed the dynamics of the early part of the virus lifecycle that we couldn't easily see with other types of treatment," Ribeiro said. "It's as if we used a microscope."

Other macaques were treated with an antibody that depletes the CD8⁺ T cells, eliminating their role in fighting the infection. A third cohort of macaques received both treatments.

The Los Alamos team then ran the model to analyze the macaque data to determine the effects of the different immune responses. From the model they inferred the most relevant immune mechanisms that more closely described the observed data.

More information: Benjamin B. Policicchio et al, CD8+ T cells control SIV infection using both cytolytic effects and non-cytolytic suppression of virus production, *Nature Communications* (2023). DOI: 10.1038/s41467-023-42435-8

Provided by Los Alamos National Laboratory



Citation: Study refines understanding of T cells' action in HIV immune response (2023, November 1) retrieved 9 May 2024 from <u>https://medicalxpress.com/news/2023-11-refines-cells-action-hiv-immune.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.